Who Paid My Doc
Ryan Charette
Adult Reconstructive Orthopaedic Surgery Wallingford, CT Medical Doctor
NPI 1396130639 CMS profile 2541749
863 North Main Street, Extension, Suite 200, 2Nd Floor, Wallingford, CT 06492
General payments
$16,348
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Ryan Charette of Wallingford, CT is reported in the CMS Open Payments database as having received $16,348 across 62 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 59th percentile of Adult Reconstructive Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $10 | 1 | |
| 2024 | General | $454 | 5 | |
| 2023 | General | $293 | 5 | |
| 2022 | General | $541 | 10 | |
| 2021 | General | $8,354 | 25 | |
| 2020 | General | $5,716 | 5 | |
| 2019 | General | $980 | 11 |
Beside peers
- Ryan Charette
- Adult Reconstructive Orthopaedic Surgery median
- Middle half of Adult Reconstructive Orthopaedic Surgery
- National median
In program year 2025, general payments to Ryan Charette were reported at $10. Among 1,079 Adult Reconstructive Orthopaedic Surgery profiles paid that year, the median was $1,406 and the middle half received between $318 and $8,709.
Show as a table
| Year | Ryan Charette | Adult Reconstructive Orthopaedic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $980 | $1,416 | $292–$9,336 | $163 |
| 2020 | $5,716 | $647 | $141–$6,474 | $114 |
| 2021 | $8,354 | $1,073 | $211–$6,497 | $132 |
| 2022 | $541 | $1,217 | $236–$6,299 | $149 |
| 2023 | $293 | $1,082 | $246–$6,818 | $160 |
| 2024 | $454 | $1,575 | $323–$8,944 | $164 |
| 2025 | $10 | $1,406 | $318–$8,709 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
1,113
Drug cost
$7,674
Branded share of claims
1.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Celecoxib | Generic | 195 | $3,706 | |
| Oxycodone Hcl | Generic | 231 | $1,031 | |
| Cephalexin | Generic | 217 | $956 | |
| Ondansetron Hcl | Generic | 176 | $811 | |
| Methylprednisolone | Generic | 53 | $471 | |
| Meloxicam | Generic | 90 | $249 | |
| Naproxen | Generic | 15 | $110 | |
| Tramadol Hcl | Generic | 45 | $105 | |
| Amoxicillin | Generic | 59 | $92 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 16 | $88 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 76 billing codesPaid by Medicare
$196,192
Medicare patients
379
Services billed
3,396
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Chronic kidney disease | 29% | |
| Diabetes | 28% | |
| Ischemic heart disease | 25% | |
| Atrial fibrillation | 23% | |
| Depression | 22% | |
| Osteoporosis | 22% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 116 | 215 | $155 |
| Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 | Office | 22 | 28 | $7 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
62 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adult Reconstructive Orthopaedic Surgery in Connecticut
Jenna Bernstein
Adult Reconstructive Orthopaedic Surgery · Trumbull, CT
Paul Murray
Adult Reconstructive Orthopaedic Surgery · Hartford, CT
Christopher Lynch
Adult Reconstructive Orthopaedic Surgery · Branford, CT
Thomas Hickernell
Adult Reconstructive Orthopaedic Surgery · Stamford, CT
Arthur Manoli
Adult Reconstructive Orthopaedic Surgery · Wilton, CT
Elie Mansour
Adult Reconstructive Orthopaedic Surgery · New Haven, CT
Related records
Adult Reconstructive Orthopaedic Surgery in Connecticut
Practitioners in the same specialty and state, ranked by reported value.
All Adult Reconstructive Orthopaedic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Connecticut
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.